Cardiac tumors secondary prevention: Difference between revisions
(Mahshid) |
|||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{Cardiac tumors}} | {{Cardiac tumors}} | ||
{{CMG}} ; {{AE}} {{Dj}} | |||
==Overview== | |||
The secondary prevention can be used in the treatment of cardiac tumors in children to prevent the adverse effects of [[Anthracyclines]]. [[Anthracyclines]] are commonly used in the treatment of cardiac malignancy in children. | |||
==Secondary Prevention== | |||
Definition: [[Secondary prevention]] focuses on early illness identification and targets persons who appear healthy but have subclinical disease types. The subclinical disease is characterized by pathologic alterations, but lacks overt manifestations that can be diagnosed during a doctor's visit. | |||
Echocardiograph can be used for screening in patients with Tuberous sclerosis and other genetic syndromes and help in secondary prevention. | |||
*The concept of secondary prevention is effective in the chemotherapeutic treatment of cardiac tumors in children. | |||
**Most pharmaceutical approaches for long-term tumor survivors exposed to cardiotoxic medications have been adopted from investigations of adults. | |||
**The lifestyle changes and reduction of cardiac risk factors after the development of cardiac failure due to chemo. constitute secondary prevention. | |||
**To avoid the development of silent LVSD to clinical disease, these measures include proactive screening and administration of '''angiotensin-converting enzyme (ACE) inhibitors and Beta-blockers.'''<ref name="pmid30768157">{{cite journal| author=Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S | display-authors=etal| title=Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. | journal=Cardiovasc Res | year= 2019 | volume= 115 | issue= 5 | pages= 922-934 | pmid=30768157 | doi=10.1093/cvr/cvz031 | pmc=6452306 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30768157 }} </ref> | |||
==References== | ==References== | ||
| Line 11: | Line 24: | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Cardiovascular system]] | [[Category:Cardiovascular system]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
Latest revision as of 14:27, 14 June 2022
|
Cardiac tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac tumors secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cardiac tumors secondary prevention |
|
Risk calculators and risk factors for Cardiac tumors secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Template:Dj
Overview
The secondary prevention can be used in the treatment of cardiac tumors in children to prevent the adverse effects of Anthracyclines. Anthracyclines are commonly used in the treatment of cardiac malignancy in children.
Secondary Prevention
Definition: Secondary prevention focuses on early illness identification and targets persons who appear healthy but have subclinical disease types. The subclinical disease is characterized by pathologic alterations, but lacks overt manifestations that can be diagnosed during a doctor's visit.
Echocardiograph can be used for screening in patients with Tuberous sclerosis and other genetic syndromes and help in secondary prevention.
- The concept of secondary prevention is effective in the chemotherapeutic treatment of cardiac tumors in children.
- Most pharmaceutical approaches for long-term tumor survivors exposed to cardiotoxic medications have been adopted from investigations of adults.
- The lifestyle changes and reduction of cardiac risk factors after the development of cardiac failure due to chemo. constitute secondary prevention.
- To avoid the development of silent LVSD to clinical disease, these measures include proactive screening and administration of angiotensin-converting enzyme (ACE) inhibitors and Beta-blockers.[1]
References
- ↑ Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S; et al. (2019). "Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment". Cardiovasc Res. 115 (5): 922–934. doi:10.1093/cvr/cvz031. PMC 6452306. PMID 30768157.